229 related articles for article (PubMed ID: 27376143)
1. A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma.
Knapp DW; Ruple-Czerniak A; Ramos-Vara JA; Naughton JF; Fulkerson CM; Honkisz SI
Bladder Cancer; 2016 Apr; 2(2):241-250. PubMed ID: 27376143
[No Abstract] [Full Text] [Related]
2. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
Knapp DW; Glickman NW; Widmer WR; DeNicola DB; Adams LG; Kuczek T; Bonney PL; DeGortari AE; Han C; Glickman LT
Cancer Chemother Pharmacol; 2000; 46(3):221-6. PubMed ID: 11021739
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.
Arnold EJ; Childress MO; Fourez LM; Tan KM; Stewart JC; Bonney PL; Knapp DW
J Vet Intern Med; 2011; 25(6):1385-90. PubMed ID: 22092632
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Henry CJ; McCaw DL; Turnquist SE; Tyler JW; Bravo L; Sheafor S; Straw RC; Dernell WS; Madewell BR; Jorgensen L; Scott MA; Higginbotham ML; Chun R
Clin Cancer Res; 2003 Feb; 9(2):906-11. PubMed ID: 12576466
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder.
Boria PA; Glickman NW; Schmidt BR; Widmer WR; Mutsaers AJ; Adams LG; Snyder PW; DiBernardi L; de Gortari AE; Bonney PL; Knapp DW
Vet Comp Oncol; 2005 Jun; 3(2):73-80. PubMed ID: 19379215
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
Mutsaers AJ; Mohammed SI; DeNicola DB; Snyder PW; Glickman NW; Bennett PF; de Gortari AE; Bonney PL; Knapp DW
Prostaglandins Leukot Essent Fatty Acids; 2005 Mar; 72(3):181-6. PubMed ID: 15664302
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.
Maeda S; Sakai K; Kaji K; Iio A; Nakazawa M; Motegi T; Yonezawa T; Momoi Y
Sci Rep; 2022 Jan; 12(1):4. PubMed ID: 35027594
[TBL] [Abstract][Full Text] [Related]
8. Identification of a naturally-occurring canine model for early detection and intervention research in high grade urothelial carcinoma.
Dhawan D; Ramos-Vara JA; Utturkar SM; Ruple A; Tersey SA; Nelson JB; Cooper BR; Heng HG; Ostrander EA; Parker HG; Hahn NM; Adams LG; Fulkerson CM; Childress MO; Bonney PL; Royce C; Fourez LM; Enstrom AW; Ambrosius LA; Knapp DW
Front Oncol; 2022; 12():1011969. PubMed ID: 36439482
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.
Inkol JM; Hocker SE; Mutsaers AJ
PLoS One; 2021; 16(8):e0255591. PubMed ID: 34352013
[TBL] [Abstract][Full Text] [Related]
11. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mohammed SI; Bennett PF; Craig BA; Glickman NW; Mutsaers AJ; Snyder PW; Widmer WR; DeGortari AE; Bonney PL; Knapp DW
Cancer Res; 2002 Jan; 62(2):356-8. PubMed ID: 11809678
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.
Marvel SJ; Séguin B; Dailey DD; Thamm DH
Vet Comp Oncol; 2017 Dec; 15(4):1417-1427. PubMed ID: 28217972
[TBL] [Abstract][Full Text] [Related]
13. Meloxicam in Combination with Mitoxantrone or Vinblastine as First-Line Treatment for Non-Resectable Urothelial Cell Carcinoma in Dogs.
Ciriano Cerdà E; Zajc AL; Finotello R; Macdonald K; Lyseight F; Van Den Steen N; Sanchez Gonzalez K; Marrington M; Grant J
Vet Sci; 2023 Aug; 10(8):. PubMed ID: 37624316
[TBL] [Abstract][Full Text] [Related]
14. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder.
Knapp DW; Richardson RC; Chan TC; Bottoms GD; Widmer WR; DeNicola DB; Teclaw R; Bonney PL; Kuczek T
J Vet Intern Med; 1994; 8(4):273-8. PubMed ID: 7983623
[TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs.
Robat C; Burton J; Thamm D; Vail D
J Small Anim Pract; 2013 Feb; 54(2):67-74. PubMed ID: 23286739
[TBL] [Abstract][Full Text] [Related]
16. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study.
de la Rosa F; Garcia-Carbonero R; Passas J; Rosino A; Lianes P; Paz-Ares L
J Urol; 2002 Jun; 167(6):2413-8. PubMed ID: 11992048
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors.
Knapp DW; Richardson RC; Bottoms GD; Teclaw R; Chan TC
Cancer Chemother Pharmacol; 1992; 29(3):214-8. PubMed ID: 1733554
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
Upton ML; Tangner CH; Payton ME
J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
[TBL] [Abstract][Full Text] [Related]
19. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development.
Knapp DW; Ramos-Vara JA; Moore GE; Dhawan D; Bonney PL; Young KE
ILAR J; 2014; 55(1):100-18. PubMed ID: 24936033
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.
Hahn NM; Bonney PL; Dhawan D; Jones DR; Balch C; Guo Z; Hartman-Frey C; Fang F; Parker HG; Kwon EM; Ostrander EA; Nephew KP; Knapp DW
J Urol; 2012 Jan; 187(1):302-9. PubMed ID: 22099988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
